The Power and Promise of Patient-Derived Xenografts of Human Breast Cancer

In 2016, a group of researchers engaged in the development of patient-derived xenografts (PDXs) of human breast cancer provided a comprehensive review of the state of the field.In that review, they summarized the clinical problem that PDXs might address, the technical approaches to their generation (including a discussion of host animals and transplant conditions tested), and presented transplantation success (take) rates across groups and across transplantation conditions.At the time, there were just over 500 unique PDX models created by these investigators representing all three clinically defined subtypes (ER + , HER2 + , and TNBC).Today, many of these PDX resources have at least doubled in size, and several more PDX development groups now exist, such that there may be well upward of 1000 PDX models of human breast cancer in existence worldwide.They also presented a series of open questions for the field.Many of these questions have been addressed.However, several remain open, or only partially addressed.Herein, we revisit these questions, and recount the progress that has been made in a number of areas with respect to generation, characterization, and use of PDXs in translational research, and re-present questions that remain open.These open questions, and others, are now being addressed not only by individual investigators, but also large, well-funded consortia including the PDXNet program of the National Cancer Institute in the United States, and the EuroPDX Consortium, an organization of PDX developers across Europe.Finally, we discuss the new opportunities in PDXbased research.